PhonlamaiPhoto Zimmer Biomet's (NYSE:ZBH) share price has been under considerable pressure over the past 3 months, potentially due to a combination of soft growth, poor cash flows and higher interest rates. Some of these issues are expected to begin correcting later in the year though. I previously suggested that concerns over the impact of weight loss drugs was misplaced, with reduced obesity rates likely to provide a demand boost in the near term. The rise of robotic surgeries and Zimmer's evolving produc ...